Shrank is president and co-founder of cell and gene therapy (CGT) startup Aradigm, which is working with patients, payers, ...
Specialty trend reached $62.25 PMPM (+11.1%), largely from utilization growth in oncology, immunology, and dermatology; ...
After step-up dosing, treatment with bispecific antibodies does not require the use of steroids, Adams noted, so patients are ...
Self-insured employers and other payers are the startup's customers, but Aradigm CEO and co-founder Will Shrank says the ...
UnitedHealthcare’s scale makes its 30% prior-authorization reduction especially consequential, signaling reputational and ...
The Wall Street Journal reports that FDA Commissioner Marty Makary is being fired, signaling imminent leadership disruption ...
Will Shrank, M.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is leading a startup ...
Financial hardship correlated strongly with nonadherence, with 37.3% of nonadherent participants unable to get by financially ...
Cross-sectional secondary analyses used SF-36 pain interference responses and medical-record diagnoses to operationalize ...
With the January 1, 2027 deadline looming, there remains a disconnect between early-stage momentum and execution maturity. On ...
Politico and The Washington Post report Makary will resign Tuesday, ending a turbulent 13-month period overseeing drug, ...
Per-capita medical costs increased 7.9% to $8,460 in 2026, while a modeled family of four reached $37,824 under employer-sponsored coverage. Outpatient facility spend grew 7.5% to ~31% of total costs, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results